Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Minireview cung cấp cho các bạn kiến thức về ngành y đề tài: Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. | Open Access Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection Monica C Panelli Mitchell E Stashower Herbert B Slade Kina Smith Christopher Norwood Andrea Abati Patricia Fetsch Armando Filie Shelley-Ann Walters Calvin Astry Eleonora Aricó Yingdong Zhao Silvia Selleri Ena Wang and Francesco M Marincola Addresses Immunogenetics Section Department of Transfusion Medicine Clinical Center National Institutes of Health Bethesda MD 20892 USA. The Clinical Skin Center of Northern Virginia Fairfax VA 22033 USA. 3M Pharmaceuticals St Paul MN 55144-1000 USA. Department of Dermatology National Naval Medical Center Bethesda MD 20889 USA. Laboratory of Pathology National Cancer Institute Bethesda MD 20892 USA. Biometric Research Branch Division of Cancer Treatment and Diagnosis National Cancer Institute Bethesda MD 20892 USA. Universita degli Studi di Milano Department of Human Morphology via Mangiagalli 20133 Milan Italy. Correspondence Francesco M Marincola. Email Fmarincola@ Published 15 January 2007 Genome Biology 2007 8 R8 doi gb-2007-8-1-r8 The electronic version of this article is the complete one and can be found online at http 2007 8 1 R8 Received 15 August 2006 Revised 6 October 2006 Accepted 12 January 2007 2007 Panelli et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma BCC and other cutaneous malignancies. We hypothesized that the characterization of the early transcriptional events induced by imiquimod may provide insights about immunological events preceding
